Strain Name:

C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J

Stock Number:

006912

Availability:

Repository- Live

Use Restrictions Apply, see Terms of Use

Description

Strain Information

Type Coisogenic; Mutant Strain; Transgenic;
Additional information on Genetically Engineered Mutant Mice.
Mating System+/+ sibling x Hemizygote         (Female x Male)
Specieslaboratory mouse
GenerationN?+F1/N?+N1 (11-DEC-07)
 
Donating Investigator Vijay Kuchroo,   Brigham and Women's Hospital

Description
Mice hemizygous for this "2D2 TCR" (or MOG 35-55 specific TCR) transgene are viable and fertile. The myelin oligodendrocyte glycoprotein (MOG)-specific transgenic T cells are not deleted nor tolerized and are functionally competent. The majority of thymocytes in 2D2 TCR mice express high and intermediate levels of the transgenic T cell receptor (TCR), indicating efficient positive selection of transgenic T cells. The majority of CD4+ splenocytes express the transgenic TCR (as defined by Valpha3.2 and Vbeta11 expression). Cultured splenocytes are responsive to whole myelin oligodendrocyte glycoprotein (MOG) and to MOG 35-55 peptide, but not to ovalbumin (OVA) control peptides. From between 2.5 to 5 months of age, 4% of 2D2 TCR mice develop spontaneous experimental autoimmune encephalomyelitis (EAE), while within the first year 40% of 2D2 TCR mice develop spontaneous, isolated optic neuritis with neither clinical nor histological evidence of EAE. Standard EAE induction protocols produce typical EAE in 2D2 TCR mice, but injection of suboptimal doses of MOG is sufficient to trigger the optic neuritis without stimulating widespread EAE in the central nervous system (CNS). Because the spontaneous diseases observed in 2D2 TCR mice are similar in their incidence and manifestations to those developed by multiple sclerosis (MS) patients, these mice may be useful in immunological studies to investigate the role and nature of the MOG-specific, self-reactive T cell repertoire, as well as to study optic neuritis and its relationship to the development of autoimmunity in the CNS.

Development
A myelin oligodendrocyte glycoprotein (MOG) peptide (amino acids 35?55; MEVGWYRSPFSRVVHLYRNGK) was injected into C57BL/6 mice. T lymphocytes from lymph nodes of these immunized mice were isolated and cells expressing the T cell receptor (TCR) combination (Valpha3.2 and Vbeta11) were selected (clone 2D2). The Valpha3.2-Jalpha18 and Vbeta11-DJbeta1.1 sequences of 2D2 TCR were cloned into TCR expression cassettes and the resulting constructs were injected into the pronuclei of fertilized C57BL/6 oocytes. Founder mice were bred with C57BL/6J mice. These 2D2 TCR transgenic mice were bred with wildtype C57BL/6 for many generations prior to arrival at The Jackson Laboratory.

Control Information

  Control
   Noncarrier
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Related Strains

Strains carrying other alleles of Tcra
005308   B10.Cg-H2d Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ
005895   B10.Cg-Thy1a H2d Tg(TcraCl1,TcrbCl1)1Shrm/J
002761   B10.Cg-Tg(TcrAND)53Hed/J
003147   B10.D2-Hc1 H2d H2-T18c/nSnJ-Tg(DO11.10)10Dlo/J
003199   B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg/J
002116   B6.129S2-Tcratm1Mom/J
005023   B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J
005655   B6.Cg-Tg(Tcra,Tcrb)3Ayr/J
008006   B6.Cg-Tg(Tcra51-11.5,Tcrb51-11.5)AR206Ayr/J
005236   B6.Cg-Tg(TcraY1,TcrbY1)416Tev/J
007962   B6.FVB-Tg(MMTV-neu/OT-I/OT-II)CBnel Tg(Trp53R172H)8512Jmr/J
002115   B6;129S2-Tcratm1Mom/J
004694   B6;D2-Tg(TcrLCMV)327Sdz/JDvsJ
002408   B6;SJL-Tg(TcrAND)53Hed/J
004364   C.Cg-Tcratm1Mom Tcrbtm1Mom/J
003303   C.Cg-Tg(DO11.10)10Dlo/J
003831   C57BL/6-Tg(TcraTcrb)1100Mjb/J
004194   C57BL/6-Tg(TcraTcrb)425Cbn/J
005307   CBy.Cg-Thy1a Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ
005922   CBy.Cg-Thy1a Tg(TcraCl1,TcrbCl1)1Shrm/J
007080   CByJ.B6-Tg(TcraTcrb)1100Mjb/J
005694   D1Lac.Cg-Tg(Tcra,Tcrb)24Efro/J
004444   NOD.129P2(C)-Tcratm1Mjo/DoiJ
006436   NOD.Cg-(Gpi1-D7Mit346)C57BL/6J Tg(TcraAI4)1Dvs/DvsJ
004257   NOD.Cg-Prkdcscid Tg(TcrLCMV)327Sdz/Dvs
004259   NOD.Cg-Rag1tm1Mom Tg(TcraAI4)1Dvs/+ Tg(TcrbAI4)1Dvs/+
004347   NOD.Cg-Rag1tm1Mom Tg(TcraAI4)1Dvs/DvsJ
005686   NOD.Cg-Thy1a Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ
004696   NOD.Cg-Tg(TcrLCMV)327Sdz/DvsJ
004460   NOD.Cg-Tg(TcraBDC2.5)1Doi Tg(TcrbBDC2.5)2Doi/DoiJ
005868   NOD.Cg-Tg(TcraTcrbNY8.3)1Pesa/DvsJ
006303   NOD.FVB-Tg(TcraBDC12-4.1)10Jos/GseJ
004334   NOD/ShiLt-Tg(TcraAI4)1Dvs
003868   NOD/ShiLt-Tg(TcraAI4)1Dvs/+ Tg(TcrbAI4)1Dvs/+
002597   STOCK Tg(TcrHEL3A9)1Mmd/J
View Strains carrying other alleles of Tcra     (35 strains)

Strains carrying other alleles of Tcrb
005308   B10.Cg-H2d Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ
005895   B10.Cg-Thy1a H2d Tg(TcraCl1,TcrbCl1)1Shrm/J
002761   B10.Cg-Tg(TcrAND)53Hed/J
003147   B10.D2-Hc1 H2d H2-T18c/nSnJ-Tg(DO11.10)10Dlo/J
003200   B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRB)C14Jg/J
002122   B6.129P2-Tcrbtm1Mom Tcrdtm1Mom/J
002118   B6.129P2-Tcrbtm1Mom/J
005023   B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J
005655   B6.Cg-Tg(Tcra,Tcrb)3Ayr/J
008006   B6.Cg-Tg(Tcra51-11.5,Tcrb51-11.5)AR206Ayr/J
005236   B6.Cg-Tg(TcraY1,TcrbY1)416Tev/J
007962   B6.FVB-Tg(MMTV-neu/OT-I/OT-II)CBnel Tg(Trp53R172H)8512Jmr/J
002121   B6;129P-Tcrbtm1Mom Tcrdtm1Mom/J
002117   B6;129P2-Tcrbtm1Mom/J
004694   B6;D2-Tg(TcrLCMV)327Sdz/JDvsJ
002408   B6;SJL-Tg(TcrAND)53Hed/J
004364   C.Cg-Tcratm1Mom Tcrbtm1Mom/J
003303   C.Cg-Tg(DO11.10)10Dlo/J
003831   C57BL/6-Tg(TcraTcrb)1100Mjb/J
004194   C57BL/6-Tg(TcraTcrb)425Cbn/J
003540   C57L/J-Tg(Tcrb)93Vbo/J
003447   CBy.129P2(B6)-Tcrbtm1Mom/SzJ
005307   CBy.Cg-Thy1a Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ
005922   CBy.Cg-Thy1a Tg(TcraCl1,TcrbCl1)1Shrm/J
007081   CByJ.129P2(B6)-Tcrbtm1Mom/J
007080   CByJ.B6-Tg(TcraTcrb)1100Mjb/J
005694   D1Lac.Cg-Tg(Tcra,Tcrb)24Efro/J
006437   NOD.Cg-(Gpi1-D7Mit346)C57BL/6J Tg(TcrbAI4)1Dvs/DvsJ
004257   NOD.Cg-Prkdcscid Tg(TcrLCMV)327Sdz/Dvs
004259   NOD.Cg-Rag1tm1Mom Tg(TcraAI4)1Dvs/+ Tg(TcrbAI4)1Dvs/+
004348   NOD.Cg-Rag1tm1Mom Tg(TcrbAI4)1Dvs/DvsJ
005686   NOD.Cg-Thy1a Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ
004696   NOD.Cg-Tg(TcrLCMV)327Sdz/DvsJ
004460   NOD.Cg-Tg(TcraBDC2.5)1Doi Tg(TcrbBDC2.5)2Doi/DoiJ
005868   NOD.Cg-Tg(TcraTcrbNY8.3)1Pesa/DvsJ
006304   NOD.FVB-Tg(TcrbBDC12-4.1)82Gse/GseJ
003868   NOD/ShiLt-Tg(TcraAI4)1Dvs/+ Tg(TcrbAI4)1Dvs/+
004335   NOD/ShiLt-Tg(TcrbAI4)1Dvs
002597   STOCK Tg(TcrHEL3A9)1Mmd/J
View Strains carrying other alleles of Tcrb     (39 strains)

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms
      assigned by genotype

Tg(Tcra2D2,Tcrb2D2)1Kuch/0

        involves: C57BL/6
  • life span-post-weaning/aging
  • abnormal induced morbidity/mortality (MGI Ref ID J:83278)
    • 40% of transgenic mice succumb to EAE compared to no non-transgenic littermates
  • nervous system phenotype
  • CNS inflammation (MGI Ref ID J:83278)
    • 7/15 mice without EAE show typical myelinating/demyelinating lesions of optic neuritis
    • mice with EAE show typical myelinating/demyelinating lesions of optic neuritis
    • 55 and 78% of transgenic mice immunized with 100 and 10 ug of MOG 35-55 without PT, respectively, develop optic nerve lesions
  • abnormal optic nerve morphology (MGI Ref ID J:83278)
    • mice with or without EAE that display optic neuritis have myelinating/demyelinating lesions consisting of subpial and endoneurial mononuclear cell infiltrates with demyelination indicated by presence of foamy macrophages
  • axon degeneration (MGI Ref ID J:83278)
    • mice with optic neuritis have varying degrees of axonal injury and loss
  • demyelination (MGI Ref ID J:83278)
    • CNS tissues show myelin loss
  • vision/eye phenotype
  • abnormal eye morphology (MGI Ref ID J:83278)
    • superficial eye lesions in mice without EAE are often associated with progressive atrophy of the eye
    • 67% of mutants show these eye lesions compared to no wild-type
    • abnormal optic nerve morphology (MGI Ref ID J:83278)
      • mice with or without EAE that display optic neuritis have myelinating/demyelinating lesions consisting of subpial and endoneurial mononuclear cell infiltrates with demyelination indicated by presence of foamy macrophages
    • blepharitis (MGI Ref ID J:83278)
      • mice without EAE develop superficial inflammation around the eyelids; this is unilateral and not observed in wild-type littermates during up to 1 year observation
    • eyelid edema (MGI Ref ID J:83278)
      • mice without EAE show eyelid inflammation and eyelid swelling; this is unilateral and not observed in wild-type littermates during up to 1 year observation
  • immune system phenotype
  • CNS inflammation (MGI Ref ID J:83278)
    • 7/15 mice without EAE show typical myelinating/demyelinating lesions of optic neuritis
    • mice with EAE show typical myelinating/demyelinating lesions of optic neuritis
    • 55 and 78% of transgenic mice immunized with 100 and 10 ug of MOG 35-55 without PT, respectively, develop optic nerve lesions
  • abnormal CD4-positive T cell morphology (MGI Ref ID J:83278)
    • CD4/CD8 single positive ratio in thymus of transgenic mice is biased toward CD4+ compartment
    • analysis shows a skewing toward CD4+ T cells in spleens as well
  • abnormal cytokine secretion (MGI Ref ID J:83278)
    • spleen cells from naive mice produce high levels of IFN gamma in response to MOG 35-55
  • blepharitis (MGI Ref ID J:83278)
    • mice without EAE develop superficial inflammation around the eyelids; this is unilateral and not observed in wild-type littermates during up to 1 year observation
  • increased susceptibility to autoimmune disorder (MGI Ref ID J:83278)
    • 4% (3/72) of mice develop spontaneous EAE, indicated initially by a limp tail, followed by hindlimb paralysis between 2.5 and 5 months of age
    • 55 and 78% of mice immunized with 100 and 10 ug of MOG 35-55 without PT, respectively, develop optic nerve lesions
    • mice with disease have typical myelinating/demyelinating lesions
    • increased susceptibility to experimental autoimmune encephalomyelitis (MGI Ref ID J:83278)
      • transgenic mice immunized with MOG 35-55 + pertussis toxin (PT) develop more severe EAE than non-transgenic littermates, with earlier onset and greater clinical scores; 50% of mice develop associated optic neuritis also
      • injection of PT alone induces clinical EAE in 39% and histological EAE in 56% of transgenics compared to no non-transgenic mice; 80% of mice develop associated optic neuritis also
  • hematopoietic system phenotype
  • abnormal CD4-positive T cell morphology (MGI Ref ID J:83278)
    • CD4/CD8 single positive ratio in thymus of transgenic mice is biased toward CD4+ compartment
    • analysis shows a skewing toward CD4+ T cells in spleens as well
  • cellular phenotype
  • increased cell proliferation (MGI Ref ID J:83278)
    • spleen cells from naive mice show increased proliferative response to myelin oligodendrocyte protein peptide 35-55 (MOG 35-55) compared to wild-type mice
  • homeostasis/metabolism phenotype
  • edema (MGI Ref ID J:83278)
    • EAE-affected mice showed edema in the brain and spinal cord
    • eyelid edema (MGI Ref ID J:83278)
      • mice without EAE show eyelid inflammation and eyelid swelling; this is unilateral and not observed in wild-type littermates during up to 1 year observation

The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.

Tg(Tcra2D2,Tcrb2D2)1Kuch/?

        involves: C57BL/6 * CD-1
  • immune system phenotype
  • abnormal interleukin physiology (MGI Ref ID J:125296)
    • T cells incubated with LPS-stimulated CD11c+ dendritic cells with IL-23 in the presence of MOG peptide and neutralizing antibodies against IFN-gamma and IL-4 plus either IL-25 or IL-13 antibodies produce less IL-17 than with both IL-25 and IL-13 antibodies or without either
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Immunology and Inflammation Research
Autoimmunity (experimental allergic encephalomyelitis (EAE))
Immunodeficiency (multiple immune defects)
Rearranged Antigen-Specific T Cell Receptor Transgenes

Research Tools
Immunology and Inflammation Research (T Cell Receptor Transgenics)
Sensorineural Research

Sensorineural Research
Eye Defects

Tcra related

Hematological Research
Immunological Defects

Immunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Immunodeficiency
Inflammation
T Cell Receptor Signaling Defects

Research Tools
Cancer Research (specific T cell deficiency)

Tcrb related

Hematological Research
Immunological Defects

Immunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Immunodeficiency
Inflammation
T Cell Receptor Signaling Defects

Genes & Alleles

Gene & Allele Information

Allele Symbol Tg(Tcra2D2,Tcrb2D2)1Kuch
Allele Name transgene insertion 1, Vijay Kuchroo
Allele Type Transgenic (random, expressed)
Common Name(s) 2D2; 2D2 TCR; TCRMOG; TCRMOG;
Mutation Made By Vijay Kuchroo,   Brigham and Women's Hospital
Expressed Gene Tcrb, T-cell receptor beta chain, mouse, laboratory
Expressed Gene Tcra, T-cell receptor alpha chain, mouse, laboratory
Molecular Note The Valpha3.2Jalpha18 region of Tcra from the 2D2 T cell clone as well as the Vbeta11DJbeta1,1 region of Tcrb from the same 2D2 clone were inserted into TCR expression cassettes. The linearized plasmids were injected into the pronuclei of fertilized C57BL/6 oocytes. The 2D2 clone was purified from C57BL/6 mice immunized with a peptide from myelin oligodendrocyte glycoprotein. The amino acid sequence of the CDR3 region from TCR alpha is VYF CALRSY NFG and that from TCR beta is CASS LDCG ANP. [MGI Ref ID J:83278]

Genotyping

Genotyping Information

Genotyping Protocols

Tg(Tcra2D2,Tcrb2D2)1Kuch, STD PCR, vers. 1

Helpful Links

Optimizing PCR Protocols

References

References

Selected Reference(s)

Bettelli E; Pagany M; Weiner HL; Linington C; Sobel RA; Kuchroo VK. 2003. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 197(9):1073-81. [PubMed: 12732654]  [MGI Ref ID J:83278]

Additional References

Tg(Tcra2D2,Tcrb2D2)1Kuch related

Awasthi A; Carrier Y; Peron JP; Bettelli E; Kamanaka M; Flavell RA; Kuchroo VK; Oukka M; Weiner HL. 2007. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 8(12):1380-9. [PubMed: 17994022]  [MGI Ref ID J:127774]

Bettelli E; Baeten D; Jager A; Sobel RA; Kuchroo VK. 2006. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 116(9):2393-402. [PubMed: 16955141]  [MGI Ref ID J:114666]

Bettelli E; Sullivan B; Szabo SJ; Sobel RA; Glimcher LH; Kuchroo VK. 2004. Loss of T-bet, But Not STAT1, Prevents the Development of Experimental Autoimmune Encephalomyelitis. J Exp Med 200(1):79-87. [PubMed: 15238607]  [MGI Ref ID J:91376]

Carl JW Jr; Liu JQ; Joshi PS; El-Omrani HY; Yin L; Zheng X; Whitacre CC; Liu Y; Bai XF. 2008. Autoreactive T cells escape clonal deletion in the thymus by a CD24-dependent pathway. J Immunol 181(1):320-8. [PubMed: 18566397]  [MGI Ref ID J:137407]

Elyaman W; Kivisakk P; Reddy J; Chitnis T; Raddassi K; Imitola J; Bradshaw E; Kuchroo VK; Yagita H; Sayegh MH; Khoury SJ. 2008. Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am J Pathol 173(2):411-22. [PubMed: 18583313]  [MGI Ref ID J:138298]

Frommer F; Heinen TJ; Wunderlich FT; Yogev N; Buch T; Roers A; Bettelli E; Muller W; Anderton SM; Waisman A. 2008. Tolerance without clonal expansion: self-antigen-expressing B cells program self-reactive T cells for future deletion. J Immunol 181(8):5748-59. [PubMed: 18832734]  [MGI Ref ID J:140751]

Greve B; Weissert R; Hamdi N; Bettelli E; Sobel RA; Coyle A; Kuchroo VK; Rajewsky K; Schmidt-Supprian M. 2007. I kappa B kinase 2/beta deficiency controls expansion of autoreactive T cells and suppresses experimental autoimmune encephalomyelitis. J Immunol 179(1):179-85. [PubMed: 17579036]  [MGI Ref ID J:127765]

Guan Y; Shindler KS; Tabuena P; Rostami AM. 2006. Retinal ganglion cell damage induced by spontaneous autoimmune optic neuritis in MOG-specific TCR transgenic mice. J Neuroimmunol 178(1-2):40-8. [PubMed: 16828169]  [MGI Ref ID J:127769]

Kleinschek MA; Owyang AM; Joyce-Shaikh B; Langrish CL; Chen Y; Gorman DM; Blumenschein WM; McClanahan T; Brombacher F; Hurst SD; Kastelein RA; Cua DJ. 2007. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med 204(1):161-70. [PubMed: 17200411]  [MGI Ref ID J:125296]

Korn T; Reddy J; Gao W; Bettelli E; Awasthi A; Petersen TR; Backstrom BT; Sobel RA; Wucherpfennig KW; Strom TB; Oukka M; Kuchroo VK. 2007. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 13(4):423-31. [PubMed: 17384649]  [MGI Ref ID J:127766]

Krishnamoorthy G; Lassmann H; Wekerle H; Holz A. 2006. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 116(9):2385-92. [PubMed: 16955140]  [MGI Ref ID J:114667]

Laouar Y; Town T; Jeng D; Tran E; Wan Y; Kuchroo VK; Flavell RA. 2008. TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 105(31):10865-70. [PubMed: 18669656]  [MGI Ref ID J:140054]

Lu L; Ikizawa K; Hu D; Werneck MB; Wucherpfennig KW; Cantor H. 2007. Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity 26(5):593-604. [PubMed: 17509909]  [MGI Ref ID J:123555]

Petersen TR; Gulland S; Bettelli E; Kuchroo V; Palmer E; Backstrom BT. 2004. A chimeric T cell receptor with super-signaling properties. Int Immunol 16(7):889-94. [PubMed: 15148288]  [MGI Ref ID J:125963]

Petersen TR; Lata R; Spittle E; Backstrom BT. 2007. A chimeric TCR-beta chain confers increased susceptibility to EAE. Mol Immunol 44(14):3473-81. [PubMed: 17481734]  [MGI Ref ID J:125962]

Quintana FJ; Basso AS; Iglesias AH; Korn T; Farez MF; Bettelli E; Caccamo M; Oukka M; Weiner HL. 2008. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453(7191):65-71. [PubMed: 18362915]  [MGI Ref ID J:136052]

Shinohara ML; Kim JH; Garcia VA; Cantor H. 2008. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 29(1):68-78. [PubMed: 18619869]  [MGI Ref ID J:137879]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX11

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony, hemizygous mice are bred to wildtype siblings or to inbred C57BL/6J (Stock No. 000664).
Mating System+/+ sibling x Hemizygote         (Female x Male)
Diet Information LabDiet® 5K52/5K67

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Pricing for USA, Canada and Mexico shipping destinations View International pricing
Weeks of AgePrice*GenderGenotypes Provided
Individual Mouse Price $236.40Female or MaleHemizygous for Tg(Tcra2D2,Tcrb2D2)1Kuch
Pairs /Price*Pair Genotype
$288.65Hemizygous for Tg(Tcra2D2,Tcrb2D2)1Kuch x Noncarrier
$288.65Noncarrier x Hemizygous for Tg(Tcra2D2,Tcrb2D2)1Kuch
*Price(s) in US dollars ($)

Additional Supply Details

Supply Notes

Pricing for International shipping destinations View USA Canada and Mexico pricing
Weeks of AgePrice*GenderGenotypes Provided
Individual Mouse Price $307.40Female or MaleHemizygous for Tg(Tcra2D2,Tcrb2D2)1Kuch
Pairs /Price*Pair Genotype
$375.30Hemizygous for Tg(Tcra2D2,Tcrb2D2)1Kuch x Noncarrier
$375.30Noncarrier x Hemizygous for Tg(Tcra2D2,Tcrb2D2)1Kuch
*Price(s) in US dollars ($)

Additional Supply Details

Supply Notes

Supply Details

Standard SupplyRepository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of ~nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within 48 hours of order placement.
Supply Notes

Control Information

  Control
   Noncarrier
   000664 C57BL/6J
 
  Considerations for Choosing Controls
  USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
  International - Control Pricing Information for Genetically Engineered Mutant Strains.

General Terms and Conditions


See Terms of Use


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering and Purchasing Information

      Purchasing Information
      JAX® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries

Contracts Administration

phone:207-288-6470
fax:207-288-6655

JAX® Mice & Services Conditions of Use

“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.

No Liability

In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.

MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.

Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.


(3.2)